COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04283097
Recruitment Status : Recruiting
First Posted : February 25, 2020
Last Update Posted : May 29, 2020
Information provided by (Responsible Party):
Kangpu Biopharmaceuticals, Ltd.

Brief Summary:
This is a Phase 1 study to evaluate the safety, pharmacokinetics(PK), and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, including multiple myeloma (MM), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), indolent lymphoma, adult T-cell leukemia-lymphoma (ATL), or chronic lymphocytic leukemia (CLL). This study will assist in identifying appropriate, well tolerated doses that can be administered in subsequent studies in subjects with selected hematological malignancies.

Condition or disease Intervention/treatment Phase
Hematological Malignancies Drug: KPG-818 Phase 1

Detailed Description:

This is a Phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies. The study center(s) will be in the US.

After providing informed consent, subjects will be assessed for study eligibility at the Screening visit (Days -28 to -1). Cohorts of 3 to 6 subjects per dose level will be given escalating doses of KPG-818 during Days 1 to 21 of each 28-day cycle orally until progressive disease (PD), unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The 5 planned dose escalation cohorts will be 2, 5, 10, 20, and 30 mg followed by dose expansion. The dose of KPG-818 for the first cohort will be 2 mg/day. The highest dose level which may be tested is 30 mg KPG-818. Dose escalation will follow a 3+3 design and dose-limiting toxicity (DLT) will be assessed during the 28-day DLT evaluation period. The Safety Monitoring Committee (SMC) will be responsible for dose escalation decisions, including whether to modify the dose escalation based on the DLT observations or determine RP2D. Escalation to the Maximal Tolerated Dose (MTD) is not appropriate if activity plateaus at a lower dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Dose escalation will based on a 3+3 design followed by dose expansion. Dose-limiting toxicity will be assessed during the 28-day DLT evaluation period. Subjects who exit the study for reasons other than DLT prior to completion of the 28-day evaluation period will be replaced to ensure an adequate safety assessment at each dose level.
Masking: None (Open Label)
Masking Description: This is a open label phase 1 study.
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects With Hematological Malignancies
Actual Study Start Date : May 15, 2020
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2021

Arm Intervention/treatment
Experimental: KPG-818
KPG-818 dose escalation
Drug: KPG-818
KPG-818 is a novel lenalidomide analog and a next generation of immunomodulatory agents. KPG-818 is structurally similar to Celgene's new investigational drug, CC-220, but with much greater cereblon (CRBN) binding affinity. KPG-818 is potent in inhibiting proliferation of hematological cancer cells growth both in vitro and in vivo. The First-in-Human phase I clinical study of KPG-818 has demonstrated that KPG-818 has a good PK profile and a broad safety window.
Other Name: KPG-818 capsules

Primary Outcome Measures :
  1. Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 6 months of treatment ]
    Number of Treatment-Emergent Adverse Events(TEAE), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and changes from baseline in laboratory parameters, vital signs, and ECG.

  2. Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 28-day of treatment ]
    Maximum tolerated dose defined as the highest dose level at which 33% or less subjects experience DLT as defined by the protocol.

Secondary Outcome Measures :
  1. PK profile of KPG-818 [ Time Frame: Up to 28-day of treatment ]
    Cmax, time of the maximum observed plasma concentration (Tmax), AUC0-t, AUC from time zero extrapolated to infinity (AUC0-∞), AUC within a dosing interval (AUC0-τ), apparent total plasma clearance (CL/F), apparent total plasma clearance at steady-state (CLss/F), apparent volume of distribution (Vz/F), apparent volume of distribution at steady-state (Vss/F), and t1/2.

  2. Preliminary clinical activity [ Time Frame: Up to 6 months of treatment ]
    Objective response rate (ORR), disease control rate (DCR), time to response, duration of response (DOR), progression-free survival (PFS), event-free survival (EFS), and transplantation rate (TR). Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification 3 (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia lymphoma (ATL).

Other Outcome Measures:
  1. Biomarkers of KPG-818 [ Time Frame: Up to 6 months of treatment ]
    Aiolos and Ikaros in peripheral blood mononuclear cell (PBMC)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply.

  1. ≥ 18 years of age at the time of signing the informed consent form (ICF).
  2. Willing and able to provide written ICF.
  3. Willing and able to adhere to the study visit schedule and other protocol requirements.
  4. Hematooncological or pathological diagnosis of MM, MCL, FL, DLBCL, indolent lymphoma, ATL or CLL.
  5. For KPG-818 dose escalations and dose expansion, subjects who have relapsed from or are refractory to ALL FDA approved therapies known to provide clinical benefit for the specific disease or have failed to their last line of therapy of the hematological malignancy, be intolerant to or are not otherwise candidates for available FDA approved standard treatment known to provide clinical benefit for the specific disease.
  6. Have measurable or assessable disease.

    For Multiple Myeloma:

    • M-protein quantities ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or
    • M-protein quantities ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (UPEP) or
    • Serum free light chain (FLC) levels > 100 mg/L involved light chain and an abnormal kappa/lambda (κ/λ) ratio in subjects without detectable serum or urine M-protein or
    • For subjects with immunoglobulin (Ig) class A (IgA) myeloma whose disease can only be reliably measured by quantitative Ig measurement, a serum IgA level ≥ 0.50 g/dL.

    For MCL, FL, DLBCL, indolent lymphoma, ATL, or CLL:

    • At least 1 bidimensionally measurable lesion larger than 1.5 cm in largest dimension by computed tomography (CT), positron emission tomography-CT (PET-CT), or magnetic resonance imaging (MRI) scan.

  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. Males and females of childbearing potential must agree to use at least two methods of contraception, as detailed in Section 6.1.3, during the study treatment and continue until 3 months after the completion of study treatment.

Exclusion Criteria Participants are excluded from the study if any of the following criteria apply.

  1. Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Currently enrolled in another clinical study, except observational studies.
  3. Has known active central nervous system metastases and/or lymphomatous meningitis.
  4. Persisting toxicities related to prior anticancer treatment > Grade 1 according to NCI-CTCAE v5.0.
  5. Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period.
  6. Any of the following laboratory abnormalities:

    • Absolute neutrophil count (ANC) ≤ 1.5 × 109/L.
    • Hemoglobin ≤ 8 g/dL.
    • Platelet count < 75 000/μL.
    • Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L).
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 2.5 × upper limit of normal (ULN) or ≥ 5.0 × ULN if liver tumor is present.
    • Total bilirubin > 1.5 × ULN.
    • Potassium not within normal limits.
    • Estimated serum creatinine clearance of ≤ 60 mL/min or requiring dialysis.
  7. Subjects with gastrointestinal disease that may significantly alter the absorption of the study drug.
  8. Subjects with a prior history of malignancies, other than MM, lymphoma, or CLL, unless the subject has been free of the disease for ≥ 5 years with the exception of the following noninvasive malignancies:

    • Basal cell carcinoma of the skin.
    • Squamous cell carcinoma of the skin.
    • Carcinoma in situ.
    • Incidental histological findings of prostate cancer such as T1a or T1b using the tumor/node/metastasis classification of malignant tumors or prostate cancer that is curative.
  9. Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide.
  10. Has known or suspected hypersensitivity to the excipients contained in the formulation of investigational product (IP).
  11. Has received any of the following within the last 14 days of initiating dosing:

    • Plasmapheresis
    • Radiation therapy other than local therapy for MM associated bone lesions
    • Use of any systemic myeloma/lymphoma/CLL drug therapy.
  12. Has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IP.
  13. Prior treatment of any inhibitors of PD-1 or PD-L1 within 3 months prior to initiating dosing.
  14. Has any one of the following:

    • Clinically significant abnormal ECG finding, including QTcF interval elongation (> 480 ms), at Screening.
    • Congestive heart failure (New York Heart Association Class III or IV).
    • Myocardial infarction within 12 months prior to initiating IP.
    • Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris.
    • Peripheral neuropathy ≥ Grade 2.
    • Subject has taken a strong inhibitor or inducer of CYP3A4/5 including grapefruit, St. John's Wort or related products within 2 weeks prior to dosing and during the course of study.
  15. Has current or prior use of immunosuppressive medication within 14 days prior initiating IP. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical, or local steroid injections (eg, intra-articular injection)
    • Systemic corticosteroids at physiologic doses that do not exceed 10 mg/day of prednisone or equivalent
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  16. Subject known to test positive for human immunodeficiency virus, chronic or active hepatitis B, or active hepatitis C.
  17. Subjects with any active or uncontrolled infection.
  18. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.
  19. Subject is a female who is pregnant, nursing, or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04283097

Layout table for location contacts
Contact: Yong Guo, MD 7329105945

Layout table for location information
United States, New York
North Shore Hematology Oncology Associates Recruiting
Port Jefferson Station, New York, United States, 11776
Contact: Laura Brady, LPN    631-675-5146   
Contact: Brian Kunkel, MBA, MT    631-459-3507   
Sponsors and Collaborators
Kangpu Biopharmaceuticals, Ltd.
Layout table for investigator information
Study Director: Yong Guo, MD Kangpu Biopharmacuticals
Layout table for additonal information
Responsible Party: Kangpu Biopharmaceuticals, Ltd. Identifier: NCT04283097    
Other Study ID Numbers: KPG-818-HEM-101
First Posted: February 25, 2020    Key Record Dates
Last Update Posted: May 29, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases